sever
acut
respiratori
syndrom
coronaviru
first
identifi
wuhan
china
respons
coronaviru
diseas
outbreak
covid
declar
pandem
world
health
organ
march
among
cov
known
caus
human
diseas
three
highli
pathogen
group
includ
sar
coronaviru
sarscov
name
middl
east
respiratori
syndrom
mer
coronaviru
merscov
agent
identifi
patient
sever
pneumonia
wuhan
china
earli
prodrom
symptom
infect
includ
anosmia
hyposmia
dysgeusia
follow
day
later
fever
cough
short
breath
fatigu
gastrointestin
symptom
includ
diarrhea
sore
throat
headach
myalgia
rare
conjunct
also
report
well
episod
confus
similar
clinic
pictur
mer
fever
chill
cough
sore
throat
wheez
short
breath
myalgia
chest
pain
gastrointestin
symptom
diarrhea
vomit
abdomin
pain
confus
may
result
although
exposur
asymptomat
mild
affect
younger
age
highest
risk
fulmin
diseas
identifi
certain
risk
factor
factor
includ
advanc
age
smoke
histori
male
gender
race
africanamerican
well
prior
medic
problem
includ
hypertens
cardiac
diseas
obes
hemorrhag
ischem
stroke
underli
respiratori
ill
asthma
emphysema
cancer
immunosuppress
secondari
infect
well
chronic
kidney
liver
diseas
peopl
die
worldwid
pandem
april
accord
recent
data
john
hopkin
univers
april
almost
million
peopl
worldwid
infect
global
mortal
rate
time
level
higher
rate
converg
current
estim
statist
reveal
may
underestim
potenti
threat
rapid
effect
test
strategi
treatment
essenti
especi
among
sever
respiratori
complic
acut
respiratori
distress
syndrom
ard
among
sickest
patient
common
reason
admiss
intens
care
unit
icu
initi
outbreak
seattl
area
hypoxem
respiratori
failur
lead
mechan
ventil
hypotens
requir
vasopressor
treatment
mortal
among
critic
ill
patient
high
icu
mortal
rate
among
requir
noninvas
ventil
one
case
seri
china
among
requir
invas
mechan
ventil
fundament
pathophysiolog
infect
potenti
result
critic
outcom
cytokin
storm
syndrom
ard
fulmin
myocard
multiorgan
dysfunct
acut
kidney
injuri
liver
dysfunct
pneumothorax
hyperinflammatori
syndrom
known
secondari
hemophagocyt
lymphohistiocytosi
shlh
macrophag
activ
syndrom
ma
also
result
fulmin
fatal
hypercytokinemia
pulmonari
involv
patient
hlhma
reveal
dyspnea
cough
common
symptom
onset
diseas
radiograph
reveal
interstiti
infiltr
centrilobular
nodul
illdefin
consolid
local
groundglass
opac
similar
radiolog
abnorm
seen
patient
recov
pneumonia
initi
lung
find
chest
ct
reveal
small
subpleur
ground
glass
opac
ggo
grew
larger
crazypav
pattern
consolid
two
week
diseas
onset
eventu
absorb
result
extens
ggo
subpleur
parenchym
band
chest
radiograph
imag
result
patient
mer
cov
also
also
shown
featur
resembl
find
organ
pneumonia
differ
howev
sar
show
fibrocellular
intraalveolar
organ
bronchiol
obliteran
organ
pneumonialik
pattern
despit
differ
initi
present
ard
report
main
caus
death
result
uncontrol
system
inflammatori
respons
releas
larg
amount
proinflammatori
cytokin
well
chemokin
immun
effector
cell
similar
pathophysiolog
seen
sar
ie
immun
cell
injurybas
damag
widespread
organ
involv
unbalanc
cytokin
chemokin
profil
address
immun
base
lung
patholog
seen
similar
seen
ard
might
help
decreas
morbid
mortal
ard
caus
lung
inflamm
increas
alveolar
endotheli
epitheli
permeabl
lead
proteinrich
pulmonari
edema
caus
sever
hypoxemia
impair
carbon
dioxid
excret
lung
injuri
noncardiogen
natur
caus
primarili
neutrophildepend
plateletdepend
damag
endotheli
epitheli
barrier
lung
frequent
caus
pneumonia
procoagul
effect
coagulopathi
antiphospholipid
antibodi
also
recent
report
patient
associ
poorer
prognosi
patient
novel
coronaviru
pneumonia
ncp
support
measur
manag
ard
includ
attent
fluid
balanc
restrict
transfus
strategi
minim
sed
neuromuscular
block
agent
along
inhal
bronchodil
shown
confer
short
term
improv
without
proven
effect
surviv
releas
proinflammatori
cytokin
tumor
necrosi
factor
alpha
interleukin
beta
interleukin
interleukin
turn
recruit
compon
innat
immun
system
shown
associ
ard
neutrophil
recruit
lung
cytokin
becom
activ
releas
toxic
mediat
lead
extens
free
radic
product
reactiv
oxygen
speci
overwhelm
endogen
antioxid
result
oxid
cell
damag
lung
tissu
pharmacolog
therapi
tri
date
includ
nitric
oxid
inhal
prostacyclin
vasoconstrictor
antiinflammatori
agent
includ
corticosteroid
corticosteroid
howev
shown
benefit
even
caus
harm
activ
nuclear
factorkappab
nfkappab
shown
requir
transcript
gene
mani
proinflammatori
mediat
associ
ard
play
key
role
orchestr
multifacet
inflammatori
respons
proinflammatori
phase
later
regul
resolut
inflamm
antiinflammatori
gene
express
antioxid
therapi
includ
nacetylcystein
nac
alpha
lipoic
acid
ala
glutathion
gsh
report
regul
signal
downregul
nfkappab
date
clinic
trial
use
either
precursor
glutathion
nac
poiv
glutathion
dyspnea
pneumonia
ard
prior
publish
control
clinic
trial
nac
demonstr
patient
ard
depress
plasma
red
cell
glutathion
concentr
level
substanti
increas
therapi
intraven
nac
measur
clinic
respons
treatment
regard
increas
oxygen
deliveri
improv
lung
complianc
resolut
pulmonari
edema
alveolar
epitheli
line
fluid
patient
ard
also
shown
defici
total
gsh
compar
normal
subject
reactiv
oxygen
speci
may
play
key
role
pathogenesi
acut
lung
injuri
ard
sinc
patient
ard
subject
increas
burden
oxid
alveolar
fluid
princip
releas
recruit
neutrophil
defici
gsh
may
predispos
patient
enhanc
lung
cell
injuri
glutathion
one
bodi
master
antioxid
shown
play
import
role
antioxid
defens
nutrient
metabol
regul
cellular
event
includ
cytokin
product
immun
respons
therefor
perform
trial
glutathion
precursor
ie
nac
antioxid
alpha
lipoic
acid
vitamin
c
along
dose
po
andor
iv
glutathion
patient
suffer
dyspnea
associ
pneumonia
previous
antibiot
treatment
pneumonia
mix
result
screen
questionnair
use
track
daili
symptom
initi
screen
questionnair
followup
form
includ
follow
symptom
track
cours
ill
loss
sens
smell
andor
tast
sore
throat
fever
sweat
chill
cough
whether
dri
product
associ
short
breath
puls
oximetri
read
avail
measur
without
oxygen
via
nasal
cannula
diarrhea
nasal
congest
sneez
rhinorrhea
conjunct
headach
myalgia
andor
arthralgia
memori
concentr
problem
white
male
white
femal
contact
offic
test
posit
either
antibodi
test
patient
radiolog
exam
chest
xray
ct
scan
consist
pneumonia
patient
patient
histori
lyme
diseas
ld
associ
tickborn
coinfect
patient
histori
persist
ld
symptom
histori
coinfect
anaplasma
babesia
posit
autoimmun
marker
short
cours
treatment
prior
year
consist
underli
chronic
inflammatori
respons
second
patient
histori
ld
bartonella
hensela
prior
exposur
rickettsia
rickettsii
rickettsia
typhi
began
treatment
neither
patient
need
exclud
prescrib
combin
therapi
base
medic
histori
allergi
intoler
medic
supplement
histori
signific
cardiac
arrhythmia
andor
qt
prolong
electrocardiogram
case
histori
patient
white
male
past
medic
histori
pmh
signific
lyme
diseas
posit
igm
western
blot
anaplasmosi
babesiosi
prior
exposur
epsteinbarr
viru
human
herpesviru
cytomegaloviru
histori
intestin
parasit
exposur
risk
tickborn
infect
includ
frequent
travel
highli
lyme
endem
area
long
island
pmh
also
includ
frequent
elev
mercuri
level
blood
hypothyroid
hypoglycemia
adren
fatigu
low
testosteron
low
vitamin
irrit
bowel
syndrom
chronic
insomnia
signific
autoimmuneinflammatori
marker
includ
histori
posit
antinuclear
antibodi
ana
rang
posit
rheumatoid
factor
normal
rang
less
neg
cyclic
citrullin
peptid
posit
igg
anticardiolipin
antibodi
autoimmun
marker
neg
includ
neg
singlestrand
dna
doublestrand
dna
sjogren
smith
antibodi
sever
month
treatment
antibiot
time
period
patient
remain
rel
good
health
never
complet
symptom
free
tickborn
infect
abl
work
high
intens
job
financi
industri
requir
followup
medic
practic
year
later
western
blot
show
old
exposur
borrelia
burgdorferi
evid
sever
lyme
specif
band
seen
januari
old
lyme
symptom
began
relaps
moder
fatigu
insomnia
sleep
hour
per
night
occasion
migratori
pain
muscl
joint
includ
low
back
shoulder
ankl
feet
along
mild
tremor
mild
cognit
dysfunct
patient
state
feel
approxim
normal
function
repeat
lab
perform
lyme
elisa
neg
igm
igg
immunoblot
neg
neg
pcr
borrelia
burgdorferi
along
neg
babesia
test
neg
test
tickborn
coinfect
rheumatoid
factor
igm
initi
elev
ana
posit
refer
rang
less
normal
highsensit
crp
normal
ferritin
level
autoimmun
marker
neg
mercuri
level
blood
elev
normal
rang
less
lead
level
blood
normal
rang
complet
blood
count
comprehens
metabol
profil
within
normal
limit
immunoglobulin
level
iga
igm
igg
miner
level
iodin
zinc
copper
magnesium
hormon
precursor
low
low
level
pregnenolon
normal
rang
ngdl
low
level
unconjug
dehydroepiandrosteron
dhea
normal
rang
ng
decilit
low
total
testosteron
level
refer
rang
ngdecilit
low
normal
level
cortisol
blood
decilit
rang
patient
call
emerg
line
medic
offic
symptom
includ
anosmia
dysgeusia
metal
tast
lowgrad
fever
fahrenheit
sweat
day
night
occasion
interf
sleep
bodi
ach
flulik
symptom
low
back
pain
dri
cough
labor
breath
scratchi
throat
sever
headach
brain
fog
diarrhea
symptom
start
one
week
prior
test
return
posit
computer
tomographi
ct
scan
emerg
room
show
left
lower
lobe
pneumonia
start
immedi
hydroxychloroquin
load
dose
mg
bid
day
follow
mg
tid
day
nitazoxanid
mg
po
bid
zithromax
mg
bid
day
also
use
albuterol
inhal
receiv
hospit
emerg
room
sever
day
prior
pump
per
day
without
signific
benefit
reliev
respiratori
symptom
along
acetaminophen
mg
q
hour
instruct
begin
antibiot
regimen
along
immun
nutrit
support
ns
includ
sever
differ
probiot
includ
acidophilu
lactobacillu
bifidobacterium
saccharomyc
boulardii
along
zinc
mg
per
day
vitamin
c
g
per
day
beta
glucan
mg
per
day
curcumin
g
twice
day
sulforaphan
glucosinol
mg
twice
day
nac
mg
twice
day
alpha
lipoic
acid
mg
twice
day
glutathion
mg
capsul
twice
day
increas
g
taken
prn
acut
respiratori
distress
also
instruct
alkal
bodi
sodium
bicarbon
andor
fresh
squeez
lemon
lime
need
use
glutathion
order
puls
oximetri
home
measur
oxygen
satur
day
postexposur
day
antibiot
regimen
day
nitazoxanid
patient
began
clinic
improv
although
still
complain
anosmia
dysgeusia
poor
appetit
cough
signific
short
breath
debilit
fatigu
sever
episod
diarrhea
per
day
dehydr
puls
oximetri
remain
higher
trial
g
oral
glutathion
tri
moder
short
breath
significantli
improv
dyspnea
within
h
home
nurs
servic
subsequ
hire
administ
iv
fluid
patient
becam
increasingli
dehydr
secondari
signific
night
sweat
diarrhea
difficulti
keep
fluid
two
gram
iv
glutathion
subsequ
administ
l
normal
salin
along
po
pedialyt
electrolyt
replac
oxygen
via
nasal
cannula
l
per
minut
sever
hour
per
day
use
prn
dyspnea
puls
oximetri
increas
nasal
cannula
relief
symptom
iv
fluid
g
glutathion
administ
h
improv
sens
wellb
quickli
improv
dyspnea
time
administ
daili
day
day
post
exposur
cough
resolv
dyspnea
bodi
ach
headach
also
significantli
improv
symptom
occasion
return
night
sweat
air
hunger
mild
linger
cough
intermitt
associ
prior
symptom
relaps
detail
discuss
patient
report
present
symptom
suggest
reactiv
babesiosi
experienc
year
prior
sinc
associ
fever
worsen
cough
signific
dyspnea
laboratori
test
present
unavail
patient
place
atovaquoneproguanil
mg
tablet
qd
day
follow
po
bid
along
oral
glutathion
dose
g
twice
day
prn
short
breath
patient
continu
improv
protocol
case
histori
patient
femal
packyear
smoke
histori
histori
three
consecut
csection
psoriasi
histori
lyme
diseas
associ
tickborn
infect
bartonella
hensela
rickettsia
rickettsii
rickettsia
typhi
diagnos
novemb
past
three
year
receiv
treatment
tickborn
ill
dramat
improv
symptomfre
treatment
past
year
prior
fall
ill
patient
healthi
eat
balanc
diet
notabl
health
complaint
sunday
march
patient
woke
f
sever
dyspnea
rest
worsen
exert
dri
cough
chest
tight
nausea
dizzi
diarrhea
sever
fatigu
bodi
pain
weak
shallow
breath
anosmia
patient
taken
emerg
room
perform
chest
xray
show
hazi
opac
peribronchi
thicken
left
mid
lower
lung
field
concern
pneumonia
possibl
atyp
patient
test
er
time
xray
due
unavail
test
nyc
given
load
dose
mg
azithromycin
emerg
room
discharg
diagnosi
suspect
novel
coronaviru
infect
atyp
pneumonia
monday
march
patient
start
combin
therapi
azithromycin
mg
po
load
dose
hydroxychloroquin
mg
po
follow
mainten
dose
hydroxychloroquin
mg
tid
day
two
day
later
amoxicillin
clavulan
mg
po
ad
extend
coverag
pneumonia
dyspnea
persist
antibiot
therapi
march
march
patient
experienc
gradual
improv
still
complain
linger
symptom
diarrhea
respiratori
symptom
includ
cough
dyspnea
rest
worsen
exert
shallow
breath
inabl
take
deep
breath
chest
tight
march
reduc
liposom
glutathion
ad
antibiot
regimen
along
mg
zinc
tid
vitamin
c
patient
given
mg
lglutathion
po
alka
seltzer
gold
along
alpha
lipoic
acid
mg
nacetylcystein
mg
patient
saw
immedi
improv
describ
abl
breath
better
energi
within
hour
use
administr
glutathion
cough
resolv
abl
sleep
night
first
time
sinc
onset
ill
despit
antibiot
regimen
sever
day
also
abl
take
deep
breath
first
time
follow
morn
administr
mg
po
glutathion
second
time
patient
abl
ambul
perform
activ
daili
live
shower
without
presyncop
episod
aris
dyspnea
first
time
could
perform
activ
daili
live
sinc
onset
ill
follow
day
addit
dose
glutathion
given
one
time
lower
dose
mg
po
therapeut
effect
higher
dose
mg
gsh
dose
glutathion
administ
patient
liposom
dose
subsequ
administ
mg
po
due
superior
efficaci
sinc
time
day
receiv
initi
dose
gsh
patient
remain
well
symptom
free
antibodi
test
readili
avail
nyc
time
present
patient
abl
receiv
pcr
test
two
week
initi
symptom
asymptomat
pcr
neg
sever
key
clinic
symptom
suggest
high
likelihood
exposur
patient
includ
constel
earli
prodrom
symptom
anosmia
hyposmia
dysgeusia
along
fever
sore
throat
cough
short
breath
apart
neurodegen
diseas
three
major
caus
loss
smell
trauma
rhinosinusitisnas
polyp
viral
infect
olfactori
gustatori
dysfunct
report
clinic
present
mildtomoder
form
coronaviru
diseas
risk
factor
includ
immunosuppress
underli
infect
patient
activ
lyme
diseas
immunosuppress
immunoglobulin
subclass
defici
well
potenti
multipl
sourc
inflamm
drive
inflammatori
process
need
consid
list
risk
factor
potenti
complic
treatment
outcom
exampl
patient
one
also
diagnos
elev
level
mercuri
contract
known
increas
free
radicaloxid
stress
glutathion
alpha
lipoic
acid
shown
import
mitig
mercuri
toxic
regul
heavi
metal
also
symptom
consist
activ
lyme
diseas
migratori
pain
multipl
posit
inflammatori
marker
posit
ana
rheumatoid
factor
migratori
pain
one
hallmark
symptom
activ
infect
borrelia
burgdorferi
differenti
diagnost
possibl
rule
rule
rheumatoid
arthriti
neg
cyclic
citrullin
peptid
lupu
erythematosu
neg
doublestrand
dna
smith
antibodi
anoth
potenti
sourc
migratori
pain
patient
suffer
lyme
diseas
relaps
fever
borreliosi
oftentim
experi
herxheim
reaction
antibiot
initi
shown
due
proinflammatori
cytokin
cytokin
express
viral
infect
glutathion
alkal
bodi
decreas
acid
byproduct
shown
help
decreas
symptomatolog
popul
patient
glutathion
metabol
also
discov
import
target
b
burgdorferi
infect
pathway
essenti
cytokin
product
like
glutathionyl
glutathion
gsh
precursor
nac
antioxid
help
regener
gsh
alpha
lipoic
acid
effect
mainstay
treat
cytokin
storm
herxheim
reaction
tickborn
popul
decad
patient
took
glutathion
first
time
day
teneleven
peak
stage
ill
accord
recent
publish
research
patient
without
sever
respiratori
distress
diseas
cours
lung
abnorm
chest
ct
greatest
sever
approxim
day
initi
onset
symptom
patient
therefor
signific
benefit
highdos
oral
glutathion
reliev
dyspnea
peak
stage
ill
patient
also
given
zinc
mg
per
day
vitamin
c
g
tid
zinc
known
play
central
role
immun
system
zincdefici
person
experi
increas
suscept
varieti
pathogen
zinc
crucial
normal
develop
function
cell
mediat
nonspecif
immun
neutrophil
natur
killer
cell
zinc
supplement
incid
infect
gener
tumor
necrosi
factor
alpha
oxid
stress
marker
shown
significantli
lower
zincsuppl
placebo
group
zinc
supplement
healthi
human
subject
also
reduc
concentr
oxid
stressrel
byproduct
plasma
inhibit
ex
vivo
induct
mrna
mononuclear
cell
mnc
provid
protect
nuclear
activ
isol
mononuclear
cell
macrophag
advers
affect
zinc
defici
dysregul
intracellular
kill
cytokin
product
also
use
vitamin
c
anoth
major
free
radic
scaveng
alpha
lipoic
acid
nac
immun
system
major
role
vitamin
c
appear
antioxid
protect
host
cell
oxid
stress
caus
infect
especi
infect
affect
lung
effect
vitamin
c
includ
increas
function
phagocyt
prolifer
tlymphocyt
product
interferon
decreas
replic
virus
alpha
lipoic
administ
simultan
vitamin
c
apart
antioxid
inhibit
airway
inflamm
increas
gsh
releas
oxid
glutathion
increas
gsh
synthesi
activ
transcript
factor
lower
express
nfkappa
b
final
nac
precursor
glutathion
given
po
dose
rang
mgday
shown
lower
inflammatori
respons
patient
commun
acquir
pneumonia
random
control
trial
increas
intracellular
gsh
improv
acut
respiratori
distress
syndrom
glutathion
abund
cell
abund
antioxid
airway
epitheli
line
fluid
act
vital
intraand
extracellular
antioxid
protect
oxid
stress
help
decreas
proinflammatori
process
lung
rapid
turnov
quickli
replenish
de
novo
synthesi
sequenti
action
two
enzym
first
gc
gammaglutamylcystein
synthesas
ligas
rate
limit
normal
function
substanti
less
maximum
capac
feedback
inhibit
gsh
respond
rapidli
gsh
requir
addit
gsh
synthesi
increas
dramat
oxid
stress
increas
gc
transcript
via
provid
adequ
avail
cystein
rate
limit
substrat
patient
took
two
activ
curcurmin
sulforaphan
glucosinol
suppress
macrophag
inflammatori
respons
block
proinflammatori
cytokin
transcript
curcumin
sulforaphan
potent
activ
shown
decreas
broad
rang
inflammatori
cytokin
includ
help
lower
inflamm
elderli
patient
shown
increas
risk
exposur
gc
activ
decreas
age
reduc
recycl
reduc
gsh
gssg
adequ
suppli
cystein
cell
larg
reserv
capac
increas
gsh
product
counter
oxid
stress
therefor
possibl
administ
larg
dose
nac
glutathion
along
zinc
vitamin
c
activ
lower
oxid
stress
inflammatori
cytokin
product
result
rapid
improv
dyspnea
clinic
symptomatolog
limit
studi
apart
small
sampl
size
howev
unabl
laboratori
test
patient
includ
check
oxid
stress
marker
lipid
peroxid
well
inflammatori
marker
crp
ferritin
ddimer
ldh
might
demonstr
chang
post
gsh
administr
random
control
trial
gsh
glutathion
precursor
inflammatoryoxid
stress
marker
done
futur
fulli
elucid
effect
block
nfkappab
determin
effect
gsh
antioxid
clinic
cours
pneumonia
ard
activ
nuclear
factorkappab
nfkappab
shown
requir
transcript
gene
mani
proinflammatori
mediat
associ
ard
intact
inflammatori
respons
play
major
role
also
requir
appropri
host
defens
virus
later
stage
bacteri
pneumonia
preclin
model
sepsi
acut
lung
injuri
associ
rapid
larg
increas
proinflammatori
cytokin
mediat
suppress
activ
shown
result
improv
surviv
nac
alphalipo
acid
gsh
inhibit
nfkappab
activ
oral
iv
glutathion
well
glutathion
precursor
nacetylcystein
alphalipo
acid
may
therefor
repres
novel
treatment
approach
block
nfkappab
address
cytokin
storm
syndrom
respiratori
distress
patient
suffer
covid
pneumonia
zinc
vitamin
c
nrf
activ
may
also
help
decreas
inflammatori
respons
lower
cytokin
product
random
control
trial
perform
evalu
efficaci
novel
therapi
treatment
patient
pneumonia
ard
view
express
dr
richard
horowitz
repres
view
tickborn
diseas
work
group
hh
unit
state
author
richard
horowitz
phylli
r
freeman
jame
bruzzes
declar
conflict
interest
funder
role
design
studi
collect
analys
interpret
data
write
manuscript
decis
publish
result
